Immune to Cancer: The CRI Blog
-
30 Days of CRI Impact
Throughout Cancer Immunotherapy Month in June we’ll be highlighting the 30 most important CRI-funded breakthroughs.
-
Second CAR T Cell Immunotherapy Approved for Patients with Lymphoma
A second CAR T cell immunotherapy targeting the CD19 receptor was approved by the FDA for patients…
-
CAR T Cell Immunotherapy Approved for Adult Non-Hodgkin Lymphoma Patients
FDA approves new immunotherapy–Yescarta (axicabtagene ciloleucel)–for adult patients with relapsed or refractory non-Hodgkin large B cell lymphoma.
-
Pembrolizumab Approved for Children and Adults with Hard-to-Treat Hodgkin Lymphoma
Pembrolizumab is second anti-PD-1 drug approved for adults with cHL, first for any childhood cancer
-
ASH 2016: Tackling Blood Cancers with Immunotherapy
The largest meeting focused on blood cancers begins December 3 in San Diego.
-
Immunotherapy for Blood Cancers: What to Look for at the Upcoming ASH Meeting
Look for the latest results from trials of PD-1 inhibitors and new developments in adoptive cell transfer.